Sanofi steps up with a $645M deal to part­ner with As­traZeneca on a late-stage RSV an­ti­body

Point­ing di­rect­ly at a piv­otal Phase III pro­gram, As­traZeneca has de­cid­ed to part­ner with Sanofi on an ex­per­i­men­tal an­ti­body for RSV.

The French phar­ma gi­ant is pay­ing €120 mil­lion up­front and up to €495 mil­lion more in de­vel­op­ment and sales mile­stones to buy in­to the pro­gram. The two Big Phar­mas will now split R&D costs for ME­DI8897, with As­traZeneca in charge of man­u­fac­tur­ing and Sanofi Pas­teur tak­ing con­trol of the com­mer­cial­iza­tion work — pro­vid­ed it goes through to an ap­proval.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN